AR and prostate carcinoma: To investigate whether the growth inhibitory effects of NXP800 were exclusively through AR signaling abrogation, we interrogated AR-positive (VCaP, LNCaP, LNCaP95, and 22Rv1) and AR-negative (PC3 and DU145) prostate cancer cell lines.